A new view towards this "old problem" of HCC recurrence is supported by recent studies showing that one class of immunosuppressants, mTOR inhibitors, is capable of not only inhibiting immune responses against transplanted allografts, they may also be potent antineoplastic agents. The gene discussed is MTOR; the disease is hepatocellular carcinoma.